Zobrazeno 1 - 10
of 31
pro vyhledávání: '"Ran, Liao"'
Autor:
Junqing Gan, Shan Liu, Yu Zhang, Liangzi He, Lu Bai, Ran Liao, Juan Zhao, Madi Guo, Wei Jiang, Jiade Li, Qi Li, Guannan Mu, Yangjiazi Wu, Xinling Wang, Xingli Zhang, Dan Zhou, Huimin Lv, Zhengfeng Wang, Yanqiao Zhang, Cheng Qian, MeiYan Feng, Hui Chen, Qingwei Meng, Xiaoyi Huang
Publikováno v:
Experimental and Molecular Medicine, Vol 54, Iss 8, Pp 1290-1305 (2022)
Prostate cancer: stem cell treatment targets microRNA A microRNA shown to promote prostate cancer growth can be targeted through a treatment derived from stem cells. Prostate cancer is lethal for many men, and its growth is promoted by testosterone.
Externí odkaz:
https://doaj.org/article/c12708f5c82040ed9721d95b911a7868
Autor:
Gerd Burmester, Josef S Smolen, Masayoshi Harigai, Kevin Winthrop, Yi-Ming Chen, Tsu-Yi Hsieh, Chad Walls, Wen-Shuo Wu, Christina Dickson, Ran Liao
Publikováno v:
RMD Open, Vol 6, Iss 1 (2020)
BackgroundReactivation of hepatitis B virus (HBV) replication is a well-recognised complication in patients receiving disease-modifying anti-rheumatic drugs (DMARDs) for rheumatoid arthritis (RA). Limited data exist on HBV reactivation among patients
Externí odkaz:
https://doaj.org/article/e82884325e2841608fb1c5a1560b4692
Autor:
Gerd Burmester, Josef S Smolen, Masayoshi Harigai, Kevin Winthrop, Yi-Ming Chen, Tsu-Yi Hsieh, Chad Walls, Wen-Shuo Wu, Christina Dickson, Ran Liao
Publikováno v:
RMD Open, Vol 6, Iss 1 (2020)
Externí odkaz:
https://doaj.org/article/1224a625565747d2b901cd185e791b4f
Autor:
Stephanie de Bono, E. Wesley Ely, Jose Francisco Kerr Saraiva, Jason D Goldman, Ran Liao, Vincent C. Marconi, Cynthia E. Kartman, Maria Lucia B. Piruzeli, Sujatro Chakladar, Athimalaipet V Ramanan
BackgroundThe oral, selective Janus kinase (JAK)1/JAK2 inhibitor baricitinib demonstrated efficacy in hospitalised adults with COVID-19. This study evaluates the efficacy and safety of baricitinib in critically ill adults with COVID-19 requiring inva
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2df57fd765d419742523e5122dfd59a3
https://doi.org/10.1101/2021.10.11.21263897
https://doi.org/10.1101/2021.10.11.21263897
Autor:
Stuart Keller, Stephanie de Bono, Douglas E Schlichting, Pierre Quartier, Ran Liao, Athimalaipet V Ramanan, Catherine Guly
Publikováno v:
Trials
Trials, Vol 22, Iss 1, Pp 1-14 (2021)
Trials, Vol 22, Iss 1, Pp 1-14 (2021)
Background Juvenile idiopathic arthritis (JIA) is the most common pediatric rheumatic disease and the most common systemic disorder associated with uveitis in childhood. Uveitis is more common in JIA patients who are antinuclear antibody (ANA)-positi
Autor:
Vincent C Marconi, Athimalaipet V Ramanan, Stephanie de Bono, Cynthia E Kartman, Venkatesh Krishnan, Ran Liao, Maria Lucia B Piruzeli, Jason D Goldman, Jorge Alatorre-Alexander, Rita de Cassia Pellegrini, Vicente Estrada, Mousumi Som, Anabela Cardoso, Sujatro Chakladar, Brenda Crowe, Paulo Reis, Xin Zhang, David H Adams, E Wesley Ely, Mi-Young Ahn, Miriam Akasbi, Javier David Altclas, Federico Ariel, Horacio Alberto Ariza, Chandrasekhar Atkar, Anselmo Bertetti, Meenakshi Bhattacharya, Maria Luisa Briones, Akshay Budhraja, Aaliya Burza, Adrian Camacho Ortiz, Roberto Caricchio, Marcelo Casas, Valeria Cevoli Recio, Won Suk Choi, Emilia Cohen, Angel Comulada-Rivera, Paul Cook, Dora Patricia Cornejo Juarez, Carnevali Daniel, Luiz Fernando Degrecci Relvas, Jose Guillermo Dominguez Cherit, Todd Ellerin, Dmitry Enikeev, Suzana Erico Tanni Minamoto, Elie Fiss, Motohiko Furuichi, Kleber Giovanni Luz, Jason D. Goldman, Omar Gonzalez, Ivan Gordeev, Thomas Gruenewald, Victor Augusto Hamamoto Sato, Eun Young Heo, Jung Yeon Heo, Maria Hermida, Yuji Hirai, David Hutchinson, Claudio Iastrebner, Octavian Ioachimescu, Manish Jain, Maria Patelli Juliani Souza Lima, Akram Khan, Andreas E. Kremer, Thomas Lawrie, Mark MacElwee, Farah Madhani-Lovely, Vinay Malhotra, Michel Fernando Martínez Resendez, James McKinnell, Patrick Milligan, Cesar Minelli, Miguel Angel Moran Rodriguez, Maria Leonor Parody, Priscila Paulin, Priscilla Pemu, Ana Carolina Procopio Carvalho, Massimo Puoti, Joshua Purow, Mayur Ramesh, Alvaro Rea Neto, Philip Robinson, Cristhieni Rodrigues, Gustavo Rojas Velasco, Jose Francisco Kerr Saraiva, Morton Scheinberg, Stefan Schreiber, Dario Scublinsky, Anete Sevciovic Grumach, Imad Shawa, Jesus Simon Campos, Nidhi Sofat, Christoph D. Spinner, Eduardo Sprinz, Roger Stienecker, Jose Suarez, Natsuo Tachikawa, Hasan Tahir, Brian Tiffany, Alexander Vishnevsky, Adilson Westheimer Cavalcante, Kapil Zirpe
Publikováno v:
The Lancet. Respiratory Medicine
Summary Background Baricitinib is an oral selective Janus kinase 1/2 inhibitor with known anti-inflammatory properties. This study evaluates the efficacy and safety of baricitinib in combination with standard of care for the treatment of hospitalised
Autor:
Mousumi Som, Jorge Alatorre-Alexander, E. Wesley Ely, Rita de Cassia Pellegrini, Xin Zhang, Venkatesh Krishnan, Sujatro Chakladar, Jason D Goldman, Stephanie de Bono, Cynthia E. Kartman, Anabela Cardoso, Ran Liao, Vicente Estrada, Brenda J. Crowe, Maria Lucia B. Piruzeli, Vincent C. Marconi, David H. Adams, Paulo Reis, Athimalaipet V Ramanan
BackgroundThe efficacy and safety of baricitinib, an oral selective Janus kinase 1/2 inhibitor, in addition to standard of care (SOC) in hospitalised adults with COVID-19 is unknown.MethodsIn this phase 3, global, double-blind, randomised, placebo-co
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d0c2c3f49dea2a7725e42733e979251b
https://doi.org/10.1101/2021.04.30.21255934
https://doi.org/10.1101/2021.04.30.21255934
Publikováno v:
Statistics in Biopharmaceutical Research
Randomized and controlled clinical trials are an important tool to provide definitive evidence about effects of treatments for COVID-19. Because of the novelty of this disease, designing these prov...
Publikováno v:
Frontiers in Public Health
Frontiers in Public Health, Vol 8 (2020)
Frontiers in Public Health, Vol 8 (2020)
Objectives: We aim to analyze equity in maternal, newborn, and child health (MNCH) interventions in Jilin, a northeastern province of China, 2008–2018.Study design: Cross-sectional study.Methods: We used provincially representative survey data from
Autor:
Mark C. Genovese, Yi-Hsing Chen, Josef S. Smolen, Ran Liao, Ilias Kouris, Marco W Wu, Patrick Durez, Jinglin Zhong, Thorsten Holzkämper, David Walker, Kevin L. Winthrop, Ricardo Machado Xavier
Publikováno v:
Rheumatology. 59
Background Baricitinib (BARI) is a selective inhibitor of janus kinase (JAK) 1 and JAK2, approved for the treatment of moderately to severely active rheumatoid arthritis (RA) in adults in over 50 countries. Objective: To evaluate the long-term safety